UK cost agency says "no" to Celgene bone marrow drug
LONDON, July 11
LONDON, July 11 (Reuters) - Celgene's drug Revlimid is not worth using on Britain's state health service because of uncertainty over whether it can extend the lives of patients with serious bone marrow disorders, the country's cost agency said on Thursday.
The draft guidance from the National Institute for Health and Clinical Excellence (NICE), if confirmed following a consultation process, would remove a treatment option for patients with myelodysplastic syndromes, which can lead to life-threatening diseases such as leukaemia.
- Insight: How U.S. spying cost Boeing multibillion-dollar jet contract
- Exclusive: Secret contract tied NSA and security industry pioneer |
- With Fed out of the way, what's next on Wall Street?
- U.S. aircraft hit by gunfire in South Sudan as conflict worsens |
- Seagram chairman, WJC head Edgar Bronfman dead at 84